Trends in Cancer

Rethinking precision oncology
Cancer drugs designed for specific molecular targets are rapidly increasing in number; however, resistance has been reported for the majority of clinically approved targeted agents. The paradigm of precision cancer medicine (PCM) needs to contend more systematically with the fact that, for each new drug, there will be manifold routes to resistance. If the PCM revolution is ever to happen, we must be just as innovative in developing new drugs as we are in understanding how best to use them.